Discovery Services

Concord provides a full range of services to support our clients in discovering and evaluating new potential drug therapies. Our full range of in vivo and in vitro metabolism, pharmacokinetic, ADME, and toxicology capabilities support you in selecting the best candidates for development.

Discovery Toxicology

Our early discovery screening and DMPK services enable clients to select candidates with the highest potential for successful development. Early toxicity evaluations enable confirmation of the selection. Expediency, accuracy and communication characterize the discovery toxicology unit at Concord.
  • Discovery support
  • DMPK and early toxicity evaluations
  • In vitro metabolite stability and profiling
  • CYP inhibition, induction, and kinetics
  • Pilot PK and metabolite identification
  • Dose range finding pilot toxicity evaluations
  • Stock colonies of canines and primates for rapid study starts

In vivo And in vitro Metabolism

We understand your need for fast turnaround in drug metabolism studies. Concord provides rapid, accurate in vitro and in vivo metabolism services that provide information required to assess your candidate’s profile and determine appropriate next steps in the development cycle. Customized in vivo studies identify pharmacokinetic parameters in animals, including metabolite profiling, disposition across tissues and organs, and structural identification of metabolites. We also provide a complete package of in vitro studies to characterize your drug candidate’s intrinsic metabolic behavior, metabolic stability, and CYP involvement, thereby assisting in prediction of clinical responses and defining concerns for subsequent studies.

Pharmacokinetics (PK) / Toxicokinetics (TK)

Kinetic profiling is essential to provide understanding of a candidate’s exposure in vivo and potential for successful development. Commonly, these studies conducted to survey or confirm species selection for preclinical development. Concord conducts a wide range of PK/TK studies in various species and uses state-of-the-art software modeling to determine parameters such as half-life, exposure (Cmax and AUC), bioavailability, clearance, and volume of distribution. Discovery kinetic studies typically involve unlabeled drug administered by the intended clinical route to allow determination and modeling of circulating parent drug and metabolite exposures. Concord maintains stock colonies of acclimated and study-ready canines and primates for fast study start times.

Pilot Toxicology

Determination of maximally tolerated dosages (MTD) in two species provides an initial in vivo toxicity assessment that is often followed by a short-term dose range finding (DRF) study involving repeated administrations. Collectively, these studies provide considerable information regarding confirmation of candidate selection, circulating exposure levels and kinetics, and toxicity profiling. At Concord, our teams efficiently initiate, execute and analyze data from these studies to provide critical information to our clients as quickly as possible.